Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.

"There's a lot of hope and hype still in the microbiome sphere," Ferring's president Per Falk tells Scrip, but the rewards could be considerable for companies that can deliver well-documented safety and efficacy data and do not take try to take shortcuts.

Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut. 

After a trial failure in 2016, four rival companies could produce pivotal data this year